$137.4 M

BCLI Mkt cap, 27-Mar-2020
Brainstorm Cell Therapeutics Net income (FY, 2019)-23.3 M
Brainstorm Cell Therapeutics EBIT (FY, 2019)-23 M
Brainstorm Cell Therapeutics Cash, 31-Dec-2019536 K
Brainstorm Cell Therapeutics EV138 M

Brainstorm Cell Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

R&D expense

1.7m1.8m2.9m4.8m4.9m2.3m977.0k8.3m17.2m

General and administrative expense

2.2m1.7m2.1m2.6m3.6m2.8m4.0m5.8m5.8m

Operating expense total

3.9m3.5m5.0m7.4m8.5m5.1m5.0m14.1m23.0m

EBIT

3.9m(3.4m)(4.9m)(7.4m)(8.5m)(5.1m)(5.0m)(14.1m)(23.0m)

Interest expense

151.0k93.0k48.0k

Interest income

132.0k1.8m

Pre tax profit

(3.4m)(5.0m)(5.0m)(13.9m)(23.3m)

Income tax expense

(5.0k)5.0k25.0k

Net Income

(3.9m)(3.4m)(4.9m)(9.2m)(8.5m)(5.0m)(5.0m)(13.9m)(23.3m)

Brainstorm Cell Therapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.9m1.3m3.5m4.3m428.0k547.0k2.5m942.0k536.0k

Accounts Receivable

312.0k24.5m

Prepaid Expenses

69.0k46.0k33.0k32.0k74.0k1.2m1.2m432.0k

Current Assets

2.3m4.9m4.4m9.6m16.8m10.4m9.6m10.3m3.4m

PP&E

314.0k247.0k258.0k313.0k271.0k297.0k392.0k651.0k960.0k

Total Assets

2.7m5.3m4.7m9.9m17.1m10.8m11.4m11.2m6.5m

Accounts Payable

244.0k358.0k228.0k1.5m1.2m22.9m1.4m4.5m14.7m

Current Liabilities

1.1m1.1m1.3m3.1m3.0m864.0k5.5m6.2m17.7m

Long-term debt

1.1m

Non-Current Liabilities

655.0k123.0k1.1m

Total Debt

1.1m

Total Liabilities

1.3m1.3m2.0m3.2m3.0m864.0k5.5m6.2m18.8m

Common Stock

6.0k7.0k8.0k11.0k11.0k11.0k11.0k11.0k

Additional Paid-in Capital

45.6m51.5m55.1m68.3m84.3m85.0m85.9m94.6m105.0m

Retained Earnings

(61.7m)(70.1m)(75.1m)(80.1m)(94.0m)(117.3m)

Total Equity

1.5m4.0m2.7m6.7m14.1m9.9m5.9m5.0m(12.2m)

Financial Leverage

1.8 x1.3 x1.7 x1.5 x1.2 x1.1 x1.9 x2.2 x-0.5 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

2.9m2.4m1.1m843.0k4.8m1.9m755.0k329.0k3.0m11.3m9.0m3.5m1.3m710.0k2.2m944.0k955.0k604.0k5.8m2.5m3.2m2.3m697.0k3.2m1.1m2.1m

Accounts Receivable

369.0k482.0k421.0k449.0k

Prepaid Expenses

49.0k38.0k148.0k137.0k53.0k43.0k135.0k55.0k34.0k48.0k88.0k36.0k114.0k117.0k80.0k67.0k82.0k176.0k230.0k86.0k1.1m1.2m1.2m1.2m917.0k619.0k

Current Assets

3.1m2.8m1.8m1.4m5.3m4.3m3.3m5.7m3.9m12.2m11.1m22.1m20.1m18.1m13.5m12.8m11.4m8.7m7.7m11.0m7.9m19.6m12.6m8.3m5.5m4.7m

PP&E

380.0k341.0k328.0k298.0k273.0k234.0k263.0k267.0k327.0k302.0k272.0k290.0k282.0k268.0k281.0k318.0k312.0k281.0k295.0k358.0k412.0k596.0k564.0k611.0k599.0k664.0k

Total Assets

3.6m3.2m2.2m1.9m5.7m4.8m3.8m6.2m4.2m12.5m11.4m22.4m20.4m18.4m13.8m13.2m11.7m9.0m8.0m11.3m9.4m21.0m13.8m11.9m8.9m7.8m

Accounts Payable

296.0k159.0k325.0k515.0k194.0k246.0k373.0k446.0k326.0k757.0k1.3m922.0k755.0k335.0k281.0k355.0k352.0k362.0k227.0k275.0k3.3m4.2m2.6m5.0m8.8m9.1m

Current Liabilities

1.3m808.0k1.3m1.5m1.1m1.1m1.2m1.4m1.6m1.8m2.4m2.7m2.5m2.8m1.2m1.3m1.2m789.0k711.0k6.1m5.6m8.1m3.8m8.5m10.5m12.0m

Long-term debt

3.0m2.8m2.6m

Non-Current Liabilities

1.7m142.0k104.0k3.0m2.8m2.6m

Total Debt

3.0m2.8m2.6m

Total Liabilities

1.4m909.0k1.4m1.6m1.3m1.3m1.4m1.7m3.3m1.9m2.5m2.7m2.5m2.8m5.6m8.1m3.8m11.5m13.4m14.6m

Common Stock

6.0k6.0k6.0k6.0k7.0k7.0k7.0k8.0k8.0k10.0k10.0k13.0k13.0k13.0k11.0k11.0k11.0k11.0k11.0k11.0k11.0k11.0k11.0k11.0k11.0k11.0k

Additional Paid-in Capital

44.2m45.0m45.8m46.0m51.4m52.1m52.5m55.7m55.4m67.1m67.8m83.5m84.0m84.3m84.5m84.8m85.0m85.1m85.2m85.5m86.2m93.9m94.2m98.3m99.4m102.8m

Retained Earnings

(58.9m)(63.9m)(66.2m)(68.8m)(71.9m)(72.9m)(74.5m)(76.9m)(77.9m)(80.4m)(82.4m)(85.5m)(88.6m)(99.0m)(103.9m)(109.6m)

Total Equity

2.2m2.3m817.0k253.0k4.5m3.5m2.4m4.5m860.0k10.6m8.9m19.7m17.8m15.5m12.6m11.9m10.5m8.2m7.3m5.2m3.8m12.9m10.0m326.0k(4.5m)(6.8m)

Financial Leverage

1.6 x1.4 x2.8 x7.3 x1.3 x1.4 x1.6 x1.4 x4.9 x1.2 x1.3 x1.1 x1.1 x1.2 x1.1 x1.1 x1.1 x1.1 x1.1 x2.2 x2.5 x1.6 x1.4 x36.4 x-2 x-1.2 x

Brainstorm Cell Therapeutics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

1.8m2.5m(872.0k)1.7m(2.9m)(1.1m)(2.6m)(3.7m)(2.1m)(4.1m)(6.5m)(2.2m)(4.5m)(7.1m)(1.8m)(2.8m)(4.4m)(1.8m)(2.8m)(5.2m)(2.3m)(5.4m)(8.6m)(5.0m)(9.9m)(15.6m)

Depreciation and Amortization

76.0k116.0k38.0k77.0k116.0k33.0k50.0k77.0k25.0k50.0k80.0k23.0k47.0k73.0k16.0k38.0k55.0k16.0k34.0k57.0k25.0k56.0k89.0k44.0k77.0k114.0k

Accounts Payable

1.0k(148.0k)81.0k271.0k(50.0k)(112.0k)15.0k88.0k98.0k529.0k1.1m(620.0k)(787.0k)(1.2m)(888.0k)(814.0k)(817.0k)17.0k(118.0k)(70.0k)1.8m2.8m1.2m481.0k4.2m4.6m

Cash From Operating Activities

(855.0k)(1.8m)(746.0k)(1.2m)(2.2m)(670.0k)(1.7m)(2.4m)(391.0k)(1.4m)(2.5m)(1.9m)(3.6m)(6.1m)(3.0m)(4.4m)(4.7m)(1.6m)(3.3m)571.0k(2.1m)(2.1m)(8.7m)(835.0k)(4.3m)(8.0m)

Purchases of PP&E

(37.0k)(38.0k)(52.0k)(61.0k)(75.0k)(20.0k)(66.0k)(97.0k)(94.0k)(94.0k)(94.0k)(16.0k)(28.0k)(26.0k)(85.0k)(96.0k)(32.0k)(118.0k)(45.0k)(260.0k)(261.0k)(4.0k)(25.0k)(127.0k)

Cash From Investing Activities

(45.0k)(46.0k)(52.0k)(61.0k)(75.0k)971.0k914.0k(2.1m)(85.0k)(87.0k)(1.7m)(13.6m)(14.1m)(12.2m)4.8m4.9m5.2m1.7m8.5m1.2m2.9m(10.2m)(5.2m)3.1m4.5m6.0m

Cash From Financing Activities

3.7m4.1m20.0k146.0k5.2m250.0k257.0k3.6m9.3m9.6m14.7m14.8m14.8m30.0k105.0k25.0k12.0m12.1m5.0k3.2m

Net Change in Cash

2.8m2.3m(778.0k)(1.1m)2.9m551.0k(562.0k)(988.0k)(476.0k)7.8m5.5m(757.0k)(2.9m)(3.5m)1.8m516.0k527.0k57.0k5.2m1.9m763.0k(221.0k)(1.8m)2.3m184.0k1.2m

Brainstorm Cell Therapeutics Ratios

USDY, 2019

EV/EBIT

-6 x

EV/CFO

-12.3 x

Financial Leverage

-0.5 x